Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy.

Atherosclerosis - 1 Jun 2003

Lahoz Carlos, Peña Rocío, Mostaza Jose M, Jiménez Javier, Subirats Enric, Pintó Xavier, Taboada Manuel, López-Pastor Angela

Abstract excerpt

Statins decrease cardiovascular morbidity and mortality, essentially, by reducing LDL-cholesterol levels and, additionally, by increasing HDL-cholesterol concentrations. Environmental and genetic factors are known to affect LDL-C response to statins but less is known regarding HDL-C. We have evaluated the lipid and lipoprotein response to 20 mg/day of pravastatin for 16 weeks in relation to the G/A polymorphism...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Apolipoprotein A-I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, HDL

Share to Heterozygote

Share to Hypercholesterolemia

Share to Osmolar Concentration

Share to Pravastatin

Share to Promoter Regions, Genetic

Source

Identifiers

PMID: 12801612
DOI: 10.1016/s0021-9150(03)00094-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy.PMID 12801612Read ↗

Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events.Semantic proximity Read ↗

Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia.Semantic proximity Read ↗

Human apolipoprotein A-I gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation.Semantic proximity Read ↗

Pharmacogenomic importance of pravastatin.Semantic proximity Read ↗

Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.Semantic proximity Read ↗

The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.Semantic proximity Read ↗

Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives.Semantic proximity Read ↗

ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.Semantic proximity Read ↗

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).Semantic proximity Read ↗

Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.Semantic proximity Read ↗

APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects.Semantic proximity Read ↗

The genetic determinants of atorvastatin response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.